{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:10:43Z","timestamp":1773738643634,"version":"3.50.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006954","name":"Tufts Medical Center;","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006954","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tupper Family Foundation"},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR002544"],"award-info":[{"award-number":["UL1TR002544"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The use of fidaxomicin is recommended as first-line therapy for all patients with Clostridioides difficile infection (CDI). However, real-world studies have shown conflicting evidence of superiority.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective single-center study of patients diagnosed with CDI between 2011 and 2021. A primary composite outcome of clinical failure, 30-day relapse, or CDI-related death was used. A multivariable cause-specific Cox proportional hazards model was used to evaluate fidaxomicin compared to vancomycin in preventing the composite outcome. A separate model was fit on a subset of patients with C. difficile ribotypes adjusting for ribotype.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 598 patients included, of whom 84 received fidaxomicin. The primary outcome occurred in 8 (9.5%) in the fidaxomicin group compared to 111 (21.6%) in the vancomycin group. The adjusted multivariable model showed fidaxomicin was associated with 63% reduction in the risk of the composite outcome compared to vancomycin (hazard ratio [HR] = 0.37; 95% confidence interval [CI], .17\u2013.80). In the 337 patients with ribotype data after adjusting for ribotype 027, the results showing superiority of fidaxomicin were maintained (HR = 0.19; 95% CI, .05\u2013.77).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In the treatment of CDI, we showed that real-world use of fidaxomicin is associated with lower risk of a composite end point of treatment failure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiae274","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:37:21Z","timestamp":1716392241000},"page":"1501-1509","source":"Crossref","is-referenced-by-count":5,"title":["The Clinical Effectiveness of Fidaxomicin Compared to Vancomycin in the Treatment of <i>Clostridioides difficile<\/i> Infection, A Single-Center Real-World Experience"],"prefix":"10.1093","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-3510","authenticated-orcid":false,"given":"Majd","family":"Alsoubani","sequence":"first","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Department of Medicine, Tufts Medical Center , Boston, Massachusetts ,","place":["USA"]},{"name":"The Stuart B. Levy Center for the Integrated Management of Antimicrobial Resistance, Tufts University School of Medicine, Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer K","family":"Chow","sequence":"additional","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Department of Medicine, Tufts Medical Center , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angie Mae","family":"Rodday","sequence":"additional","affiliation":[{"name":"Tufts Clinical and Translational Science Institute, Tufts Medical Center , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A","family":"McDermott","sequence":"additional","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Department of Medicine, Tufts Medical Center , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth T","family":"Walk","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Montana State University , Bozeman, Montana ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M","family":"Kent","sequence":"additional","affiliation":[{"name":"Predictive Analytics and Comparative Effectiveness Center, Tufts Medical Center\/Tufts University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R","family":"Snydman","sequence":"additional","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Department of Medicine, Tufts Medical Center , Boston, Massachusetts ,","place":["USA"]},{"name":"The Stuart B. Levy Center for the Integrated Management of Antimicrobial Resistance, Tufts University School of Medicine, Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"2024121523503410900_jiae274-B1","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/cid\/cis551","article-title":"Nosocomial diarrhea: evaluation and treatment of causes other than Clostridium difficile","volume":"55","author":"Polage","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024121523503410900_jiae274-B2","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/cid\/cis499","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials","volume":"55","author":"Crook","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024121523503410900_jiae274-B3","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1056\/NEJMra0707500","article-title":"Clostridium difficile\u2014more difficult than ever","volume":"359","author":"Kelly","year":"2008","journal-title":"N Engl J Med"},{"key":"2024121523503410900_jiae274-B4","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa051590","article-title":"An epidemic, toxin gene-variant strain of Clostridium difficile","volume":"353","author":"McDonald","year":"2005","journal-title":"N Engl J Med"},{"key":"2024121523503410900_jiae274-B5","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1111\/j.1572-0241.2007.01539.x","article-title":"Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1\/027","volume":"102","author":"P\u00e9pin","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"2024121523503410900_jiae274-B6","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/430315","article-title":"Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada","volume":"40","author":"P\u00e9pin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2024121523503410900_jiae274-B7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jiac.2018.05.010","article-title":"Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative phase III study in Japan","volume":"24","author":"Mikamo","year":"2018","journal-title":"J Infect Chemother"},{"key":"2024121523503410900_jiae274-B8","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"2024121523503410900_jiae274-B9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2024121523503410900_jiae274-B10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(17)30751-X","article-title":"Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b\/4 trial","volume":"18","author":"Guery","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024121523503410900_jiae274-B11","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00228-022-03376-1","article-title":"Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of Clostridium difficile infection: a systematic review and meta-analysis","volume":"78","author":"Dai","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"2024121523503410900_jiae274-B12","doi-asserted-by":"crossref","first-page":"ofad622","DOI":"10.1093\/ofid\/ofad622","article-title":"Comparative effectiveness of fidaxomicin vs vancomycin in populations with immunocompromising conditions for the treatment of Clostridioides difficile infection: a single-center study","volume":"11","author":"Alsoubani","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024121523503410900_jiae274-B13","doi-asserted-by":"crossref","first-page":"e00391-19","DOI":"10.1128\/AAC.00391-19","article-title":"U.S.-based national surveillance for fidaxomicin susceptibility of Clostridioides difficile-associated diarrheal isolates from 2013 to 2016","volume":"63","author":"Thorpe","year":"2019","journal-title":"Antimicrobial Agents Chemother"},{"issue":"(Suppl 1)","key":"2024121523503410900_jiae274-B14","doi-asserted-by":"crossref","first-page":"S391","DOI":"10.1093\/ofid\/ofx163.973","article-title":"Epidemiologic trends in Clostridium difficile isolate ribotypes in United States from 2010 to 2014","volume":"4","author":"Snydman","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2024121523503410900_jiae274-B15","doi-asserted-by":"crossref","first-page":"102185","DOI":"10.1016\/j.anaerobe.2020.102185","article-title":"Epidemiologic trends in Clostridioides difficile isolate ribotypes in United States from 2011 to 2016","volume":"63","author":"Snydman","year":"2020","journal-title":"Anaerobe"},{"key":"2024121523503410900_jiae274-B16","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024121523503410900_jiae274-B17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinbiochem.2022.03.009","article-title":"The impact of diagnostic stewardship interventions on Clostridiodes difficile test ordering practices and results","volume":"117","author":"Khuvis","year":"2023","journal-title":"Clin Biochem"},{"key":"2024121523503410900_jiae274-B18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Diseases"},{"key":"2024121523503410900_jiae274-B19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2024121523503410900_jiae274-B20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/CIRCULATIONAHA.106.614859","article-title":"Survival methods","volume":"115","author":"Rao","year":"2007","journal-title":"Circulation"},{"key":"2024121523503410900_jiae274-B21","author":"Martijn"},{"key":"2024121523503410900_jiae274-B22","volume-title":"Missing data","author":"Allison","year":"2001"},{"key":"2024121523503410900_jiae274-B23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/jcpt.12771","article-title":"Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection","volume":"44","author":"Tieu","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"2024121523503410900_jiae274-B24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmi.2018.12.007","article-title":"Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study","volume":"25","author":"Gentry","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2024121523503410900_jiae274-B25","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijid.2020.11.004","article-title":"Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection\u2014an observational cohort study","volume":"103","author":"Polivkova","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2024121523503410900_jiae274-B26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/0018578719844165","article-title":"Fidaxomicin compared with oral vancomycin for the treatment of severe Clostridium difficile-associated diarrhea: a retrospective review","volume":"55","author":"Summers","year":"2020","journal-title":"Hosp Pharm"},{"key":"2024121523503410900_jiae274-B27","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1128\/AAC.00939-15","article-title":"Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection","volume":"59","author":"Gallagher","year":"2015","journal-title":"Antimicrobial Agents Chemother"},{"key":"2024121523503410900_jiae274-B28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/ajhp\/zxz032","article-title":"Predictors of Clostridioides difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings","volume":"76","author":"Appaneal","year":"2019","journal-title":"Am J Health System Pharm"},{"key":"2024121523503410900_jiae274-B29","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.cmi.2018.06.020","article-title":"Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes","volume":"25","author":"Falcone","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2024121523503410900_jiae274-B30","doi-asserted-by":"crossref","first-page":"102142","DOI":"10.1016\/j.anaerobe.2019.102142","article-title":"Clostridioides difficile ribotype 106: a systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain","volume":"62","author":"Carlson","year":"2020","journal-title":"Anaerobe"},{"key":"2024121523503410900_jiae274-B31","doi-asserted-by":"crossref","first-page":"102440","DOI":"10.1016\/j.anaerobe.2021.102440","article-title":"Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains","volume":"72","author":"Almutairi","year":"2021","journal-title":"Anaerobe"},{"key":"2024121523503410900_jiae274-B32","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1017\/ice.2015.187","article-title":"In the endemic setting, Clostridium difficile ribotype 027 is virulent but not hypervirulent","volume":"36","author":"Aitken","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024121523503410900_jiae274-B33","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae274\/58500675\/jiae274.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/6\/1501\/61141109\/jiae274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/6\/1501\/61141109\/jiae274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T23:50:53Z","timestamp":1734306653000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/230\/6\/1501\/7680222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,23]]},"published-print":{"date-parts":[[2024,12,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae274","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,15]]},"published":{"date-parts":[[2024,5,23]]}}}